Prime Minister Mostafa Madbouly inaugurated on 28th January, 2023 a factory owned by pharmaceutical company “BioGeneric Pharma” in northern Egypt’s 10th of Ramadan City, which is set to receive the technology required to produce mRNA vaccines and biologics.

The factory construction started in 2019; production equipment was put in place in 2021, service areas and quality control laboratories were set up and the whole project was completed in 2022.

BioGeneric Pharma was chosen by the World Health Organisation (WHO) in February last year to receive the technology to produce mRNA vaccines, the rapeutic proteins, and immunoglobulins for treating cancer. The company is set to become a reginal hub for mRNA technology for Africa and low- and middle-income countries.

The factory is equipped with the most modern equipment of production and analysis; for using modern technologies in the manufacture of vaccines and biopharmaceuticals, with a high-speed production capacity.

The factory consists of three main units for the production of active pharmaceutical ingredient (API) and automatic packaging.

The first area extends over an area of 1,500 square meters and includes the manufacture of biomaterials, including bioreactors, purification and concentration technology with state-of-the-art single-use systems, and other related service areas.

The region is equipped with the most modern single-use bioreactors with a capacity ranging from 25 to 2000 liters.

The second area contains areas for preparation, including automatic packing in three types of containers. This area produces many materials without the risk of mixing them up.

The third area contains areas for preparation and automatic filling in bottles (vales) of different sizes.

The factory also contains quality control laboratories equipped with the latest testing equipment and quality control devices. The laboratories are built on an area of 1200 square meters.

The factory has 1,850 square meters of warehousing space that includes receiving, sampling and distribution areas. In addition there is a storage area for raw materials and final products. The plant constantly controls humidity and temperature by means of an electronic monitoring system. Different temperatures are also being considered to match international instructions in storing vaccines and biomaterials.